Resistance time of trametinib combined with dabrafenib

Trametinib (Trametinib) and dabrafenib (Dabrafenib) is a combination drug therapy commonly used to treat malignant melanoma with BRAF gene mutations. However, drug resistance is a common problem that can lead to drug inefficiency. According to current research and clinical trial results, the combination treatment of trametinib and dabrafenib can significantly extend patient survival and control tumor growth. However, the time when drug resistance occurs varies among individuals and there is no fixed time for drug resistance.

Despite dual blockade of the MAPK pathway by trametinib and dabrafenib, suboptimal MAPK pathway inhibition was achieved. This suggests that feedback activation of MAPK signaling may limit the effectiveness of this regimen and that EGFR may contribute to the resistance of many (but possibly not all) BRAF mutant tumor cells to BRAF inhibitors, possibly through feedback activation of RAS, thereby reactivating the MAPK pathway and other important signaling pathways.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).